Traditionally, BIO has been focused on bringing?well-established?biotech and?pharma?companies together. ?This year, the organizers wanted to shake things up?abit?and allow?NIH/NSF funded SBIR companies, some of which have zero revenue,?to showcase their business and have an opportunity to talk with investors?and C-level execs about their work?and vision for the future. ? This all occurred at the?INNOVATION Zone?in?the Exhibitor Hall throughout the conference. There were more than 50 companies?presenting?with a focus on?drug discovery, diagnostics, biofuels?and?many?other platform technologies.
There?s still time to meet with the companies. ?Below are?some highlights to give you a taste of the cutting-edge technology that was presented:
PhylloTech?developed?a method to produce large amounts of protein from?tobocca?plants that is not only cost efficient but?environmentally?safe compared to traditional methods.??
Privo?Technologies?developed a topical wafer for the treatment of oral cancer.
Humanetics?developed an oral suspension pill that patients can take?to protect them from the harmful effects of radiation therapy and diagnostic procedures.
Kiyatec?developed a?3-D cell-based phenotypic models of cancer to allow for better testing of therapeutics targets.
Novasentis?developed the world?s first digitally controlled catheter.
CytoVale?developed?a rapid label-free diagnostic platform to clinically validate hundreds of patient samples with 85% sensitivity and specificity.
Sharklet?developed?the world?s first texture designed to inhibit bacterial contamination. ?This is predominantly useful?for tubing sets used?in hospital settings where bacterial infections contribute to 10,000 deaths a year.
Phi Optics?developed a?label-free, non-invasive quantitative live cell imagining.
